Evaluation of an optimal cut-off point for the Ki-67 index as a prognostic factor in primary breast cancer: A retrospective study

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Tashima, Rumiko ^a   Nishimura, Reiki ^a   Osako, Tomofumi ^a   Nishiyama, Yasuyuki ^a   Okumura, Yasuhiro ^a   Nakano, Masahiro ^a   Fujisue, Mamiko ^a   Toyozumi, Yasuo ^a   Arima, Nobuyuki ^a  

^a KUMAMOTO CITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ADULT; AGED; ARTICLE; BREAST CANCER; CALCULATION; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DISEASE MARKER; HUMAN; IMMUNOHISTOCHEMISTRY; KI 67 INDEX; MAJOR CLINICAL STUDY; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; RETROSPECTIVE STUDY; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REFERENCE VALUE; VERY ELDERLY; YOUNG ADULT;

KI 67 ANTIGEN;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; PROGNOSIS; REFERENCE VALUES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84941313451     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119565     Document Type: Article

References (28)

1. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Kains BH, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008; 10: R65. doi: 10.1186/bcr2124 PMID: 18662380
2. Aleskandarany MA, Green AR, Rakha EA, Mohammed RA, Elsheikh SE, et al. Growth fraction as a predictor of response to chemotherapy in nodenegative breast cancer. International Journal of Cancer. 2010; 126: 1761-1769.
3. Dai H, Veer LV, Lamb J. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Research. 2005; 65: 4059-4066. PMID: 15899795
4. Finek J, Holubec L Jr, Topolcan O, Elgrova L, Skalova A, Pecen L. The importance of prognostic factors in premenopausal women with breast cancer. Anticancer Research. 2007; 27: 1893-1896. PMID: 17649790
5. Azambuja ED, Cardoso F, Castro GD, Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. British Journal of Cancer. 2007; 96: 1504-1513. PMID: 17453008
6. Ruiz C, Seibt S, Kuraya KA, Siraj AK, Mirlacher M, Schraml P, et al. Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. International Journal of Cancer. 2006; 118: 2190-2194.
7. Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med. 2010; 1: 747-754. PMID: 22993598
8. Penault-Llorca F, Andre F, Sagan C, Lacroix-Triki M, Denoux Y, Verriele V, et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor positive breast cancer. J Clin Oncol. 2009; 27: 2809-2815. doi: 10.1200/JCO.2008.18.2808 PMID: 19380452
9. Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol. 2008; 26: 5569-5575. doi: 10.1200/JCO.2008.17.0829 PMID: 18981464
10. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, et al. Strategies for subtypes - Dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol.2011; 23:2997-3006.
11. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology.2013; 25: 1-18.
12. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25: 5287-5312. PMID: 17954709
13. Arima N, Toyozumi Y, Nishimura R, Osako T, Nishiyama Y, Nakano M, et al. Pre-analytical setting is critical for an assessment of the Ki-67 labeling index for breast cancer. Cancer Res 15. 2013; 24: Supplement P1-02-01
14. Kai K, Nishimura R, Arima N, Miyayama H, Iwase H. p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study. Int J Clin Oncol. 2006; 11:426-33. PMID: 17180510
15. Kikuchi S, Nishimura R, Osako T, Toyozumi Y, Okumura Y, Nishiyama Y, et al. Definition of p53 Overexpression and its Association with the Clinicopathological Features in Luminal/HER2-negative Breast Cancer. Anticancer Res. 2013; 33: 3891-3898. PMID: 24023325
16. Taktak AF, Eleuteri A, Lake SP, Fisher AC. A web-based tool for the assessment of discrimination and calibration properties of prognostic models. Comput Biol Med 2008; 38: 785-791. doi: 10.1016/j. compbiomed.2008.04.005 PMID: 18539267
17. Harrell FE, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982; 247: 2543-2546. PMID: 7069920
18. Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009; 101: 736-750. doi: 10.1093/jnci/djp082 PMID: 19436038
19. Senkus E, Kyriakides S, Penault-Llorca F, Poortmans P, Thompson A, Zackrisson S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology.2013; 0: 1-17.
20. Nishimura R, Osako T, Nishiyama Y, Tashima R, Nakano M, Fujisue M, et al. Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - In Primary Breast Cancer. Oncology. 2013; 85: 100-110. doi: 10.1159/000353099 PMID: 23867253
21. Nishimura R, Osako T, Okumura Y, Hayashi M, Arima N. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. Breast Cancer. 2010; 17:269-275. doi: 10.1007/s12282-009-0161-5 PMID: 19730975
22. Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. 2011; 11: 486. doi: 10.1186/1471-2407-11-486 PMID: 22081974
23. Nishimura R, Osako T, Okumura Y, Tashima R, Toyozumi Y, Arima N. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J Surg Oncol. 2011; 9:131. doi: 10.1186/1477-7819-9-131 PMID: 22004841
24. Denkert C, Loib S, Müller BM, Eidtmann H, Schmitt WD, Eirmann W, et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Annals of Oncology.2013; 00: 1-8.
25. Gong P, Wang Y, Liu G, Zhang J, Wang Z. New Insight into Ki67 Expression at the Invasive Front in Breast Cancer. PLoS ONE. 2013; 8: e54912. doi: 10.1371/journal.pone.0054912 PMID: 23382998
26. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes C, Cuzick J, et al. Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2011; 103:1-9.
27. Reyal F, Hajage D, Savignoni A, Feron JG, Bollet MA, et al. Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma. PLoS One. 2013; 8: e55901. doi: 10. 1371/journal.pone.0055901 PMID: 23526930
28. Honma N, Horii R, Iwase T, Saji S, Younes M, ito Y, et al. Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy. Breast Cancer. 2013; 12: Epub ahead of print.